Breast Center ▲ Sign in to save

• ▲ Katja Krauss

  Women‘s Healthcare Group Medicine
  743

  citations

  13

  h-index

  13

  Aachen papers

1 result

• De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results.

  2021 Journal of Clinical Oncology conference-abstract Medicine HER2/EGFR in Cancer Research

  21

  citations
• ADAPTcycle: Adjuvant dynamic marker-adjusted personalized therapy (ADAPT) comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2- early breast cancer (EBC).

  2020 Journal of Clinical Oncology conference-abstract Medicine Advanced Breast Cancer Therapies

  18

  citations
• Adjuvant dynamic marker-adjusted personalized therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2- early breast cancer: ADAPTcycle.

  2022 Journal of Clinical Oncology conference-abstract Medicine Advanced Breast Cancer Therapies

  4

  citations
• Concordance and clinical impact of ER, PR, HER2 expression by local and central immunohistochemistry versus RT-PCR in HR+/HER2- early breast cancer (EBC): Results from the ADAPT trial.

  2022 Journal of Clinical Oncology conference-abstract Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies

  1

  citations

4 results